BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35434981)

  • 21. BRAF-mutated carcinomas among thyroid nodules with prior indeterminate FNA report: a systematic review and meta-analysis.
    Trimboli P; Treglia G; Condorelli E; Romanelli F; Crescenzi A; Bongiovanni M; Giovanella L
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):315-20. PubMed ID: 25920006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutational analysis using next generation sequencing in pediatric thyroid cancer reveals BRAF and fusion oncogenes are common.
    Newfield RS; Jiang W; Sugganth DX; Hantash FM; Lee E; Newbury RO
    Int J Pediatr Otorhinolaryngol; 2022 Jun; 157():111121. PubMed ID: 35397361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries.
    Vuong HG; Kondo T; Oishi N; Nakazawa T; Mochizuki K; Inoue T; Tahara I; Kasai K; Hirokawa M; Tran TM; Katoh R
    Cancer Med; 2016 Aug; 5(8):1883-9. PubMed ID: 27264674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact of BRAF mutation on the diagnosis and prognosis of papillary thyroid carcinoma: a systematic review and meta-analysis.
    Wang Z; Chen JQ; Liu JL; Qin XG
    Eur J Clin Invest; 2016 Feb; 46(2):146-57. PubMed ID: 26648183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fusion Oncogenes in Patients With Locally Advanced or Distant Metastatic Differentiated Thyroid Cancer.
    Ju G; Sun Y; Wang H; Zhang X; Mu Z; Sun D; Huang L; Lin R; Xing T; Cheng W; Liang J; Lin YS
    J Clin Endocrinol Metab; 2024 Jan; 109(2):505-515. PubMed ID: 37622214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
    Guerra A; Zeppa P; Bifulco M; Vitale M
    Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.
    Ciampi R; Romei C; Pieruzzi L; Tacito A; Molinaro E; Agate L; Bottici V; Casella F; Ugolini C; Materazzi G; Basolo F; Elisei R
    J Endocrinol Invest; 2017 Jan; 40(1):55-62. PubMed ID: 27535135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis.
    Vuong HG; Altibi AM; Duong UN; Ngo HT; Pham TQ; Tran HM; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R; Kondo T
    Tumour Biol; 2017 Oct; 39(10):1010428317713913. PubMed ID: 29037127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
    Li C; Lee KC; Schneider EB; Zeiger MA
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk Stratification Using a Novel Genetic Classifier Including
    Jung CK; Jung SH; Jeon S; Jeong YM; Kim Y; Lee S; Bae JS; Chung YJ
    Thyroid; 2020 Nov; 30(11):1589-1600. PubMed ID: 32326836
    [No Abstract]   [Full Text] [Related]  

  • 31. Associations between BRAF(V600E) and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis.
    Liu C; Chen T; Liu Z
    World J Surg Oncol; 2016 Sep; 14(1):241. PubMed ID: 27600854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Somatic RAS mutations occur in a large proportion of sporadic RET-negative medullary thyroid carcinomas and extend to a previously unidentified exon.
    Boichard A; Croux L; Al Ghuzlan A; Broutin S; Dupuy C; Leboulleux S; Schlumberger M; Bidart JM; Lacroix L
    J Clin Endocrinol Metab; 2012 Oct; 97(10):E2031-5. PubMed ID: 22865907
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.
    Stanojevic B; Dzodic R; Saenko V; Milovanovic Z; Pupic G; Zivkovic O; Markovic I; Djurisic I; Buta M; Dimitrijevic B; Rogounovitch T; Mitsutake N; Mine M; Shibata Y; Nakashima M; Yamashita S
    Endocr J; 2011; 58(5):381-93. PubMed ID: 21498916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl.
    Mitsutake N; Fukushima T; Matsuse M; Rogounovitch T; Saenko V; Uchino S; Ito M; Suzuki K; Suzuki S; Yamashita S
    Sci Rep; 2015 Nov; 5():16976. PubMed ID: 26584635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.
    Liu X; Qu S; Liu R; Sheng C; Shi X; Zhu G; Murugan AK; Guan H; Yu H; Wang Y; Sun H; Shan Z; Teng W; Xing M
    J Clin Endocrinol Metab; 2014 Jun; 99(6):E1130-6. PubMed ID: 24617711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
    Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
    Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
    Kim TH; Park YJ; Lim JA; Ahn HY; Lee EK; Lee YJ; Kim KW; Hahn SK; Youn YK; Kim KH; Cho BY; Park DJ
    Cancer; 2012 Apr; 118(7):1764-73. PubMed ID: 21882184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
    Tufano RP; Teixeira GV; Bishop J; Carson KA; Xing M
    Medicine (Baltimore); 2012 Sep; 91(5):274-286. PubMed ID: 22932786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis.
    Vuong HG; Odate T; Ngo HTT; Pham TQ; Tran TTK; Mochizuki K; Nakazawa T; Katoh R; Kondo T
    Endocr Relat Cancer; 2018 Jun; 25(6):633-641. PubMed ID: 29615431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent BRAF
    Oishi N; Kondo T; Nakazawa T; Mochizuki K; Inoue T; Kasai K; Tahara I; Yabuta T; Hirokawa M; Miyauchi A; Katoh R
    Endocr Pathol; 2017 Jun; 28(2):103-111. PubMed ID: 28176151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.